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Abstract
Cytotoxic T lymphocytes (CTLs) directed to nonviral tumor–associated antigens do not survive long
term and have limited antitumor activity in vivo, in part because such tumor cells typically lack the
appropriate costimulatory molecules. We therefore engineered Epstein-Barr virus (EBV)-specific
CTLs to express a chimeric antigen receptor directed to the diasialoganglioside GD2, a nonviral
tumor–associated antigen expressed by human neuroblastoma cells. We reasoned that these
genetically engineered lymphocytes would receive optimal costimulation after engagement of their
native receptors, enhancing survival and antitumor activity mediated through their chimeric
receptors. Here we show in individuals with neuroblastoma that EBV-specific CTLs expressing a
chimeric GD2-specific receptor indeed survive longer than T cells activated by the CD3-specific
antibody OKT3 and expressing the same chimeric receptor but lacking virus specificity. Infusion of
these genetically modified cells seemed safe and was associated with tumor regression or necrosis
in half of the subjects tested. Hence, virus-specific CTLs can be modified to function as tumor-
directed effector cells.
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Note: Supplementary information is available on the Nature Medicine website.
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The promise of tumor antigen–specific T lymphocytes for the treatment of melanoma and EBV-
associated malignancies1–7 has led to efforts to retarget effector T cells and thereby extend the
range of tumors that they can treat. A common strategy has been to introduce a synthetic
receptor with an antigen-binding domain from an antibody coupled to a signal-transducing
endodomain derived from the native T cell receptor into activated T cells (ATCs)8. These
chimeric antigen receptors (CARs) thus have the specificity of an antibody coupled to the
cytotoxic effector mechanisms of the T cell. To date, however, this strategy has had only limited
success, owing in part to the lack of essential costimulatory signals to the T cell during
engagement of its CAR and perhaps also to the introduction of the CAR into regulatory T
(Treg) cells, as well as into conventional T effector cells9. Consequently, even when the infusion
of large numbers of CAR-bearing T cells is supplemented with exogenous growth factors, such
as interleukin-2 (IL-2), survival in vivo is poor and antitumor activity minimal10,11. By contrast,
small numbers of CTLs with native receptor specificity directed to persistent human viruses
such as EBV can survive long term after infusion and eradicate even bulky EBV-associated
malignancies, such as Hodgkin’s disease and nasopharyngeal cancer2,12–14. A contributing
factor to the superior survival and function of EBV-specific CTLs is that engagement of their
native receptors by EBV-infected B cells produces extensive co-stimulation during their
preparation ex vivo and by encounters with (latent) viral antigens on antigen-presenting cells
in vivo15.
This knowledge has given rise to the concept of engineering antigen-specific CTLs to provide
them with a second specificity for tumor antigens16–18. However, many tumors generate their
own immunosuppressive environment19,20, and it is unknown whether the desirable functional
characteristics of CTLs would be retained in individuals with cancer once these cells co-express
a CAR that retargets them to a tumor-associated antigen. We therefore administered EBV-
specific CTLs expressing such a CAR to individuals with neuroblastoma to determine whether
the survival times of these CAR-CTLs are indeed longer than those of ATCs expressing the
same tumor-directed CAR. We made this comparison in the same individuals by expressing
functionally identical but molecularly distinguishable tumor-specific CARs in the two discrete
T cell populations. Thus, each subject acted as a ‘self control’, avoiding the confounding
variables otherwise inherent in a comparison of CTL versus ATC behavior in a heterogeneous
group of humans with cancer. Here we show the superior persistence and retained cytotoxicity
of CAR-CTLs compared to CAR-ATCs, as well as measurable tumor responses after infusion
of these genetically engineered cells into subjects with neuroblastoma. With additional
refinements and further clinical testing, infusion of CAR-CTLs may provide a general approach
to the cell therapy of cancer.
RESULTS
Modification, phenotype and ex vivo activity of CTLs and ATCs
Both CTLs and ATCs were transduced with a CAR directed to the GD2 antigen, which is
present on the tumor cells of most individuals with neuroblastoma, a pediatric malignancy
derived from neural crest cells21. The GD2-specific CAR vectors were made from the same
14G2a antibody16, but each incorporated a distinguishable noncoding 3′ oligonucleotide.
Through PCR analysis, these distinct signals allowed us to determine the proportion of GD2
signal coming from each vector source (Supplementary Fig. 1 and Supplementary Methods
online). These distinguishable CARs were introduced into autologous ATCs and EBV-specific
CTLs from each individual. We rotated the transducing vector between ATCs and CTLs in
consecutive subjects to ensure that apparent differences in persistence and function between
the transduced cells would not be due to differences in vector transduction efficiency or
function. Eleven individuals with neuroblastoma who had EBV-specific IgGs (indicating
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persistent virus infection) received a single injection of an equal number of CAR-CTLs and
CAR-ATCs, for a total dose of 2 × 107 to 2 × 108 cells (Table 1).
Before infusing the modified T cells, we characterized their phenotype and ex vivo function.
The transduction efficiency for both cell types was consistently above 35% (Fig. 1a,b), with a
good correlation between the percentages of positive cells found by PCR and by
immunofluorescence, with the mean (± s.d.) efficiency for ATCs exceeding that for CTLs (P
= 0.02 for each comparison). CAR-ATCs and CAR-CTLs both consisted of a polyclonal
mixture of CD4+ and CD8+ T cells with few CD56+ natural killer (NK) cells present, but the
ratio of CD4+ to CD8+ cells was consistently higher in the CTL population than in the ATC
population (P = 0.05) and covered a wider range of values (Fig. 2a). At the time of freezing,
2.2–4.4% of cells in the ATC population had a central memory (CD45RO+CCR7+CD62L+)
phenotype, whereas 42–76% had an effector memory phenotype (CD45RO+CCR7−CD62L−;
Fig. 2b). Between 23% and 44% were CD45RO− and CD45RA+ (Fig. 2b), showing the
expected mixture of naive and memory T cells22. CAR-CTLs at freezing were uniformly
CD45RO+ and CD45RA− and uniformly CCR7− and CD62L−, so their phenotype was
consistent with the presence of effector memory cells (Fig. 2b). CXCR4, (the receptor for
SDF1, a chemokine associated with marrow homing) was more highly expressed on ATCs
(P = 0.02) than on CTLs, but all other chemokine receptors and adhesion molecules tested
were comparably expressed by the two populations (Fig. 2c), suggesting that the ATCs and
CTLs would have similar trafficking properties in vivo.
To ensure that the transduced CTLs retained their EBV specificity (mediated through their
native receptor) and that both CAR-CTLs and CAR-ATCs gained specificity against GD2+
neuroblasts, we measured cytotoxic effector function against EBV+ B cells and GD2+
neuroblastoma cells. The transduced CTLs killed autologous but not allogeneic EBV+ B cells
(lymphoblastoid cell lines, LCLs), whereas the transduced ATCs failed to kill either of these
targets (Fig. 2d). Conversely, an allogeneic GD2+ neuroblast line (LAN-1), which expresses
few major histocompatibility complex (MHC) class I molecules, was effectively killed by both
CAR-CTLs and CAR-ATCs (Fig. 2d). As expected, therefore, CAR-CTLs recognize and kill
EBV+ target cells through their native receptor (in an MHC-restricted manner), whereas both
CAR-CTLs and CAR-ATCs kill GD2+ neuroblasts through their MHC-unrestricted chimeric
receptor.
In vivo persistence of modified CTLs and ATCs
We anticipated that the CAR-CTLs would persist at an initially higher level than the CAR-
ATCs because of the additional co-stimulation they received ex vivo from the EBV antigens
expressed by autologous lymphoblastoid cell lines23 and subsequently persist longer because
they had the advantage of activation through their native receptors by endogenous antigen and
concomitant co-stimulation from EBV-infected B cells24. Thus, in each subject, we measured
the PCR signal from the vector associated with CAR-CTLs and from the vector associated with
CAR-ATCs. As expected, within 24 h of infusion, the PCR signal from the CAR-CTLs
consistently reached higher levels than that from the CAR-ATCs and was detectable beyond
6 weeks, compared to only 3 weeks for the modified ATCs (Fig. 3). These higher initial and
subsequent CAR-CTL numbers in the circulation seem to be the consequence of in vitro and
then in vivo native antigen receptor engagement rather than the result of any intrinsic
differences in antigen-independent survival between CAR-ATCs and CAR-CTLs
(Supplementary Table 1, Supplementary Figs. 2 and 3, and Supplementary Results online).
Overall, the mean ± s.e.m. area under the curve (positive cells × duration of signal) was more
than tenfold higher for CAR-CTLs than for CAR-ATCs (0.189 ± 0.082 vs. 0.014 ± 0.004, P =
0.05; Fig. 3).
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It is unlikely that the number of effector cells infused had a substantial impact on the outcome
of the experiments. Indeed, as we have previously observed21, the percentages of gene-
modified ATCs and CTLs in peripheral blood do not change if larger numbers of cells are
infused15. Nor were these percentages increased in the present study after partial
lymphodepletion mediated by monoclonal antibodies to CD45 (ref. 25) (Supplementary
Results). It is also possible that the observed differences in the numbers and persistence of
CAR-ATCs versus CAR-CTLs in peripheral blood resulted from increased trafficking to
marrow by CAR-ATCs, which typically express the CXCR4 receptor, or by immediate
trafficking to tumor sites. However, less than half of the ATC population (mean 43.8%)
expressed CXCR4 (Fig. 2c), and marrow aspirates and tumor biopsies lacked evidence of
increased CAR-ATC infiltration (data not shown).
CAR-CTLs show sustained proliferation and cytotoxicity in vivo
CAR-expressing CTLs and ATCs introduced into individuals with advanced cancer can
become anergic20. This functional loss has multiple causes, including increased numbers and
activity of Treg cells and secretion of inhibitory cytokines such as transforming growth factor-
β by the tumor itself19,26. We therefore asked whether the CAR-CTLs in peripheral blood at
4–24 weeks after infusion had become unresponsive. After culturing peripheral blood
mononuclear cells (PBMCs) from six individuals with their autologous EBV-expressing B
cells, we measured the intensity of the CAR-derived signal by PCR amplification (Fig. 4).
Even after 24 weeks in the treated subjects, the CAR-CTLs consistently expanded in response
to native receptor stimulation by EBV+ target cells (Fig. 4b, Supplementary Fig. 4 and
Supplementary Results online), resulting in a 2–20-fold enrichment of PCR signal. We found
no evidence for such expansion in the CAR-ATC population (Fig. 4a), although highly specific
methods for selective expansion of CAR-ATCs in ex vivo cultures are lacking. Enrichment of
CAR DNA was accompanied by a corresponding enrichment of CAR expression on the cell
surface (Fig. 4c). To show that these CAR-enriched cells (from a 2-week sample) also retained
cytotoxic activity against cells targeted through both native and chimeric receptors, we cultured
them with autologous EBV+ targets and allogeneic GD2+ neuroblasts and confirmed the
persistence of recognition and killing through both native and chimeric receptors (Fig. 4d).
Hence, even after prolonged in vivo survival, the CAR-expressing CTLs can remain responsive
to signals through their native receptors and retain tumor-directed cytotoxic effector function
through the chimeric receptors. By contrast, CAR-ATCs could not be detected among
mononuclear cells in peripheral blood (even after mitogen stimulation) and thus were not
available for assessment.
Tumor responses after infusion of modified T cells
Eleven individuals with neuroblastoma were treated with CAR-CTLs and CAR-ATCs. Four
of the eight with evaluable tumors had evidence of tumor necrosis or regressions (summarized
below), including a sustained complete remission (Table 1). None developed detectable
antibodies to CAR-CTLs, and there were no adverse events attributable to the genetically
modified T cells in the 11 subjects followed for up to 24 months.
Subject 3, a 4-year-old female whose disease was refractory to high-dose chemotherapy and
radiation, had a persistent lesion (4 cm) in the left parietal region of the skull. This mass arose
from the bone, extended into the extradural space (Fig. 5a) and accumulated meta-
iodobenzylguanidine (MIBG). The extradural component resolved within 6 weeks after
treatment, and the MIBG scan became negative 4 months later. This subject has remained in
complete remission for more than 12 months without further therapy.
Subject 6, a 15-year-old female with recurrent disease after chemotherapy, irradiation and
double autologous stem cell transplantation, had extensive marrow disease repeatedly
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documented on bilateral bone biopsies (Fig. 5b). Re-examination 4 weeks after treatment
revealed no residual tumor in either biopsy site, but 4 weeks later extramedullary disease
became evident (data not shown).
Subject 8, a 5-year-old female with recurrent disease after chemotherapy, irradiation, and
autologous stem cell transplantation, had a slowly progressing lesion (10 cm) in the left scapula.
Two weeks after cell infusion, she developed fever, local (axillary) lymphadenopathy and then
pain at the site of the tumor. Computed tomography imaging showed necrosis in the scapular
lesion and axillary lymph nodes (data not shown); necrosis was confirmed by biopsy
(Supplementary Fig. 5 online). A residual tumor persisted, but its size remained stable at 12
months after treatment (data not shown).
Subject 10, a 6-year-old female with recurrent disease after chemotherapy, radiation and
autologous stem cell transplantation, had multiple metastatic lesions (2–6 cm) in the liver.
Twelve days after receiving the modified T cells, she developed fever and hepatalgia.
Computed tomography imaging showed hyperlucency of the multiple liver lesions (data not
shown), a finding indicative of necrosis that was subsequently confirmed on biopsy
(Supplementary Fig. 6 online). The liver lesions were rapidly resurgent (data not shown),
leading to the subject’s death at 4 months after treatment.
We were unable to relate these responses to the clinical characteristics of the individual tumors
(such as size, extent or genetic markers) or to the infused dose of the genetically engineered T
cells. Needle biopsy specimens of necrotic tumor sites from subjects 6, 8 and 10, although
revealing T cell infiltrates, lacked PCR signal for CAR-CTLs or CAR-ATCs, suggesting that
the observed tumor responses may have resulted from indirect mechanisms of cytotoxicity27.
DISCUSSION
Our results show that human virus-specific CTLs expressing a synthetic chimeric antigen
receptor directed to a nonviral tumor–associated antigen persist in higher numbers and for
longer times after administration to individuals with cancer than do activated T cells expressing
the same receptor but lacking viral specificity. Moreover, these engineered CTLs retain the
ability to recognize both virus-infected and tumor targets through their native and chimeric
receptors, respectively, and their infusion may be associated with subsequent tumor necrosis
or sustained complete remission. Hence, virus-specific CTLs seem to offer distinct advantages
as tumor-directed effector cells.
The chimeric antigen receptor we describe was derived from a combination of an antibody and
a T cell receptor, but retargeting may also be achieved by cloning the MHC-peptide–binding
α and β chains of the native T cell receptor (TCR-αβ) itself and transferring them to polyclonal
T cells1,28. Although encouraging results have been obtained1, the αβ receptors are MHC
restricted, so that multiple receptors and vectors must be made to cover common MHC
polymorphisms for every peptide. More problematically, many tumors, including
neuroblastoma, evade T cell immune responses by down-regulating their MHC expression or
by degrading their antigen-processing mechanisms19,29,30. Thus, T cells expressing αβ
receptors may be of value for only a restricted number of tumors.
A limitation of CAR-mediated T cell therapy has been the brief persistence of the engineered
cells, even when they are infused in large numbers. We suggest that CAR-CTLs were able to
overcome this limitation in the present study (Fig. 3) because of the ex vivo and subsequent in
vivo antigen stimulation and co-stimulation they received after engagement of their native
receptor. The almost immediate difference in survival seen between CAR-CTLs and CAR-
ATCs at less than 24 h after infusion is unlikely to have resulted from differences in in vivo
proliferation and more probably reflects the greater ability of CAR-CTLs to recirculate in the
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peripheral blood, perhaps by avoiding trapping in capillary beds31. The subsequent survival
advantage of CAR-CTLs over CAR-ATCs does not seem to be an artifact resulting from
differences in the intrinsic, antigen-independent survival ability of the two populations
(Supplementary Figs. 2 and 3), but rather a consequence of continuing native receptor
stimulation by latent EBV antigen on endogenous antigen-presenting cells. Both in vitro and
in vivo preclinical studies have shown16,18 that CAR-CTL survival requires continued native
receptor stimulation; otherwise, these cells cease to divide and undergo apoptosis within 2–3
weeks (Supplementary Fig. 4). Moreover, in an earlier clinical study15, we adoptively
transferred an autologous CTL monoculture containing EBV-, cytomegalovirus (CMV)- and
adenovirus-specific CTLs to stem cell transplant recipients and observed persistence of the
autologous CMV-specific and EBV-specific CTLs in the latently infected CMV- and EBV-
seropositive recipients. By contrast, adenovirus-specific CTLs persisted only when there was
concomitant adenovirus infection of the recipient (and thus antigen stimulation). Because the
CMV-, EBV- and adenovirus-specific CTLs used in the study had all received the same in
vitro stimulation and co-stimulation from the same antigen-presenting cells, we concluded that
native receptor stimulation in vitro is insufficient to produce subsequent long-term persistence
of CTLs in peripheral blood and that in vivo engagement of the native receptor is required as
well.
Our CTLs and ATCs each expressed a chimeric receptor containing only the ζ-chain of the T
cell receptor. An alternative means of preparing CAR+ T cells is to incorporate additional
costimulatory endodomains such as CD28 into the CAR32 or to express transgene-encoded
costimulatory ligands from the effector T cell itself33. These strategies initiate costimulatory
signaling to the nucleus after CAR engagement and thereby help to compensate for the lack of
physiological co-stimulation when chimeric receptors engage most tumor cells32. Despite
promising results in preclinical testing34, such constitutively expressed ‘compound’ CARs
cannot mimic the complicated temporal or spatial pattern of costimulatory signals required for
the full and sustained activation and function of effector T cells, suggesting that they may
undergo suboptimal activation unless the targeted tumor itself expresses a range of additional
costimulatory receptors or ligands34. By contrast, when virus-infected B cells engage EBV-
CTLs through their native receptor, a panoply of physiological co-stimulation follows35,
increasing the likelihood of an effective T cell response. Similarly, in our study, the T cells
were activated ex vivo by a CD3 mitogenic antibody (OKT3) alone before transduction. Other
investigators have used a mixture of OKT3 and the costimulatory molecule CD28 to prepare
ATCs. Although this combination may facilitate ex vivo expansion of ATCs to the larger
numbers infused in those studies, the transience of the activation response to CD28 and its
incompleteness as a costimulatory signal26–29 means that such cells may not have in vivo
survival superior to that of the OKT3-stimulated ATCs used here36.
We found no correlation between the dose of the genetically modified cells infused and their
subsequent numbers in peripheral blood, and neither of these measures correlated with tumor
response, a result similar to previous observations13,14. Indeed, with few exceptions, the precise
mechanisms by which T lymphocytes damage or destroy solid human tumors in vivo are far
from defined7,14. Although it is possible that earlier tumor biopsies would have enabled
detection of gene-modified cells, an alternative explanation is that effective T cell–based cancer
therapies stimulate an immune cascade involving multiple types of antitumor effector cells,
including T lymphocytes with different origins and different antigen specificities from those
actually infused27,28. Nonetheless, given that functional CAR-CTLs persist after infusion, we
suggest that the EBV-specific CAR–expressing CTLs, rather than the modified ATCs, initiated
the tumor responses and necrosis observed in this study. It is noteworthy that even large
numbers of CAR-ATCs (>1 × 109 cells) have failed to influence tumor survival or growth in
previous studies10, supporting a clinically important antitumor contribution from the EBV-
specific CTLs expressing the chimeric antigen receptor. Thus, we have shown that a CAR
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introduced into virus-specific CTLs has biological advantages over an identical CAR
introduced into OKT3-activated primary T cells. This general model will probably be of value
in studies of other combinations of CARs and native receptors17,37 and may yield improved
clinical results as we implement refinements made on the basis of a better understanding of
the antitumor mechanisms involved1,31.
METHODS
Subjects
This study was open to individuals who had recurrent or refractory advanced-stage
neuroblastoma or were unable to receive or complete standard therapy (Table 1). All were
seropositive for IgG specific for the viral capsid antigen of EBV, had appropriate organ function
and performance scores and lacked human antibodies to mouse antigen or to rat antigen. We
obtained 30–60 ml of peripheral blood for production of EBV-transformed LCLs,
phytohemagglutinin blasts, and gene-modified ATCs and EBV-CTLs under current ‘good
tissue practice’ conditions. The investigation was approved by the US Food and Drug
Administration, the Recombinant DNA Advisory Committee and the Institutional Review
Board of Baylor College of Medicine. All participants or their guardians gave informed consent
on enrollment. Assent given by the participants was as is appropriate for their age and level of
development.
We treated subjects with single infusions of CAR-ATCs and CAR-CTLs at the doses given in
Table 1 and evaluated them for tumor responses 4–6 weeks after infusion38. We assessed
toxicity on the basis of physical examinations, performance tests and laboratory tests of organ
function conducted at 1, 2, 4 and 6 weeks after infusion and again at 3, 6, 9 and 12 months
after infusion. We tested the retroviruses for their replication competence before the study and
at 3, 6, and 12 months after infusion.
Generation of retroviral constructs
The retroviral vector encoding the scFv domain targeting the GD2a antigen has been previously
described16. To generate two PCR-distinguishable retroviral constructs (Zeta-5 and Zeta-6),
we opened SFG.lacZ (a splicing Maloney murine leukemia virus–based vector generously
provided by R.C. Mulligan)39 with NcoI and BamHI, removing the lacZ gene. We generated
a pair of double-stranded DNA cassettes with XhoI- and BamHI-compatible ends by annealing
oligonucleotides with sequences 5′-TCGAACGCGTCATCATC-3′ with 5′-
CTAGCTACTACT GCGCA-3′ and oligonucleotides with sequences 5′-
TCGATGCATGCAAC CTC-3′ with 5′-CTAGCTCCAACGTACGT-3′, respectively. We
cloned the chimeric receptor with either of these cassettes into the opened SFG vector to
generate the Zeta-5 and Zeta-6 vectors, which on confirmatory sequencing differed only in a
12–base pair stretch between the receptor stop codon and the 3′ long terminal repeat. This 12–
base pair stretch includes an MluI site in Zeta-5 and an SphI site in Zeta-6.
Generation and validation of retrovirus packaging cell lines
We transfected the Phoenix Eco cell line (American Type Culture Collection SD3444) with
vectors Zeta-5 or Zeta-6 to generate a pseudotyped transient supernatant, which we used
repeatedly to transduce PG13 cells (gibbon ape leukemia virus pseudotyping packaging cell
line; American Type Culture Collection CRL-10686). We detected the GD2-specific CAR by
FACS analysis on the transduced PG13 cells with the idiotypic antibody 1A7 (TriGem, Titan
Pharmaceutical)16. After single-cell cloning, we used the highest-titer clone for each vector to
establish a master cell bank. We released the clones for clinical use only after safety testing
and vector sequencing; none produced replication-competent retrovirus. We stored the final
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viral supernatant at −80 °C and tested it before clinical release. Virus titers ranged from 6 ×
105 to 1.6 × 106 virus particles per ml.
Generation and transduction of activated T cells and cytotoxic T cells
To generate CAR-ATCs, we transduced PBMCs, activated them with OKT3 (Ortho Biotech)
antibody and recombinant human IL-2 (rhIL-2, 100 U ml−1, Proleukin Chiron) in 24-well plates
precoated with a recombinant fibronectin fragment (FN CH-296, Retronectin Takara). At 48
h after transduction, we expanded T cells with rhIL-2 (50 U ml−1) added every 3 d. We
generated EBV-CTLs as previously described23 with PBMCs stimulated with gamma-
irradiated (40 Gy) autologous LCLs. For transduction, we plated EBV-CTLs (obtained after
at least three stimulations) in retronectin-coated 24-well plates with the retroviral supernatant.
We transduced CAR-ATCs on day 3 after culture initiation and froze them on day 15 (± 3 d),
and we transduced CAR-CTLs on day 23 (± 5 d) after culture initiation and froze them on day
45 (± 9 d).
Immunophenotyping
We stained ATC and CTL lines with monoclonal antibodies to CD3, CD4, CD8, CD56, CD19,
TCR-αβ, TCR-γδ, CD62L, CD27, CD28, CD45RA, CD45RO, CCR2, CCR4, CCR5, CCR7,
CXCR3, CXCR4, CD162, CD54, CD38, CD106, CD11a, CD11c and CD18 (Becton-
Dickinson). We included control samples labeled with appropriate isotype-matched antibodies
in each experiment. We detected the 14g2a CAR with the idiotypic antibody 1A7 (ref. 16). We
analyzed the cells by FACScan (Becton-Dickinson) equipped with a filter set for four
fluorescence signals.
Chromium release assay
We evaluated the cytotoxic specificity of ATCs and EBV-CTLs with a standard 4-h 51Cr
release assay, as previously described8,17.
Real-time quantitative PCR
We used quantitative PCR to quantify the retrovirus integrants for both the Zeta-5 and the
Zeta-6 vectors in PBMCs. After DNA extraction with the QIAamp DNA Blood Mini Kit
(Qiagen), we amplified the DNA in duplicate with primer and probe sequences (Applied
Biosystems) for the Zeta-5 and Zeta-6 vectors in the ABI Prism 7700 Sequence Detector
(Perkin-Elmer). The baseline range was set at cycles 6–15 with the threshold at ten standard
deviations above the baseline fluorescence. To generate DNA standards, we established single-
cell clones from the Jurkat cell line and transduced them with either Zeta-5 or Zeta-6. We
serially diluted DNA obtained from these clones with DNA extracted from nontransduced
control Jurkat cells (Supplementary Fig. 1 and Supplementary Methods).
Before and at different times afterinfusion, we extracted DNA was extracted from the PBMCs
of subjects. We amplified both marker sequences as described above and plotted the results as
the mean percentage of positive cells for all 11 subjects, with a known positive cloned line
used as a reference standard. Comparison of mean ± s.e.m. areas under the curve for ATCs and
CTLs was based on data from the primary PCR analysis above.
Statistical analyses
We relied on descriptive statistics (means, ranges and standard deviations or standard errors)
to summarize most datasets. We compared the data by the two-tailed t-test or by the
nonparametric Wilcoxon signed-rank test (area-under-the-curve analysis). Differences with a
P value of <0.05 were considered statistically significant.
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Transduction of CTLs and ATCs with GD2-specific CARs. (a) Transduction efficiency of
subject-derived CTLs and ATCs by the GD2 vectors, as evaluated by quantitative PCR (qPCR,
left) and FACS (right). Each symbol represents 1 of the 11 individual subjects, and the
horizontal lines indicate the mean group value. Surface expression by FACS and qPCR
amplification are described in Methods. (b) FACS analyses of receptor expression shown in
more detail for subject 5. Percentages represent the proportion of transduced cells.
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Immunophenotypes of CAR-transduced CTLs and ATCs. (a) Phenotypic composition of CTL
and ATC population after transduction with the GD2-specific CARs. Percentages of CD4+ and
CD8+ T cells, natural killer cells (CD3−CD56+) and T cells expressing TCR-γδ are shown.
Each symbol represents a transduced cell line infused into a single subject. A significant
difference between CTLs and ATCs was observed only for the percentage of CD8+ cells (P =
0.05). (b) Expression of naive, central memory and effector memory surface markers on GD2-
specific CAR-CTLs and CAR-ATCs. The data are means ± s.d. (c) Expression of chemokine
receptors and adhesion molecules on GD2-specific CAR-CTLs and CAR-ATCs. The data are
means ± s.d. (d) Results of standard 51Cr release assay at an effector:tumor cell (E:T) ratio of
20:1. Data represent the mean ± s.d. percentage of specific chromium released from the CAR-
CTLs and CAR-ATCs generated from each of the 11 subjects. Targets were autologous LCLs,
allogeneic LCLs, autologous PHA blasts and LAN-1 cells.
Pule et al. Page 13














In vivo persistence of infused CAR-CTLs versus CAR-ATCs in peripheral blood as determined
by real-time quantitative PCR. A comparison of mean ± s.e.m. areas under the curve of the
qPCR signal for ATCs and CTLs detected in PBMCs of treated subjects at the indicated times
after infusion is shown. Five of the subjects (7 –11) received monoclonal antibodies to the
common leukocyte antigen (CD45)25 at 2–3 d before ATC and CTL infusion and had 44–91%
depletion of endogenous circulating lymphocytes25. There were no measurable differences
between the areas under the curve for either ATCs or CTLs between subjects 1–6 (no CD45)
and 7–11 (CD45-treated).
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Reactivation of CAR-CTLs ex vivo. (a,b) Fold change in the level of GD2-receptor-transgene
positivity in the cultures before and after exposure to EBV antigen in ATCs (a) and CTLs
(b). PBMCs were collected at increasing times after infusion (indicated on the x axis) and re-
expanded ex vivo in the presence of EBV+ targets (total of three or four stimulations). Each
symbol represents a single subject. (c) Change in percentage of cells expressing the GD2
chimeric receptor on ex vivo-reactivated CTLs. The y axis for the top panels indicates the
isotype control, whereas for the bottom panels it indicates antibody 1A7. Percentages represent
the proportions of cells expressing the CAR. (d) Cytotoxicity of ex vivo-reactivated CTLs
against autologous LCLs, allogeneic LCLs or LAN-1 cells. The data are means ± s.d. of
triplicate experiments.
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Resolution of neuroblastoma in subjects 3 and 6 after infusion of genetically engineered T
cells. (a) Sequential anatomic (MRI) and functional (MIBG) imaging of the head and neck of
subject 3, a 4-year-old girl with relapsed metastatic neuroblastoma, with an extradural mass
and overlying calvarial bone involvement. Progressive resolution of the extradural mass and
loss of MIBG uptake in the lesion by 4 months after infusion are indicated by arrows. The
signal in the salivary glands remains due to normal uptake. (b) H&E stain showing postinfusion
normalization of bone marrow in subject 6 after extensive infiltration by neuroblasts.
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